Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

The discovery and identification of a candidate proteomic biomarker of active tuberculosis

Authors: Jiyan Liu, Tingting Jiang, Liliang Wei, Xiuyun Yang, Chong Wang, Xing Zhang, Dandan Xu, Zhongliang Chen, Fuquan Yang, Ji-Cheng Li

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Noninvasive and convenient biomarkers for early diagnosis of tuberculosis (TB) remain an urgent need. The aim of this study was to discover and identify potential biomarkers specific for TB.

Methods

The surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS) combined with weak cation exchange (WCX) magnetic beads was used to screen serum samples from 180 cases of TB and 211 control subjects. A classification model was established by Biomarker Pattern Software (BPS). Candidate protein biomarkers were purified by reverse phase-high performance liquid chromatography (RP-HPLC), identified by MALDI-TOF MS, LC-MS/MS and validated using enzyme-linked immunosorbent assay (ELISA).

Results

A total of 35 discriminating m/z peaks were detected that were related to TB (P < 0.01). The model of biomarkers based on the four biomarkers (2554.6, 4824.4, 5325.7, and 8606.8 Da) was established which could distinguish TB from controls with the sensitivity of 83.3% and the specificity of 84.2%. The candidate biomarker with m/z of 2554.6 Da was found to be up-regulated in TB patients, and was identified as a fragment of fibrinogen, alpha polypeptide isoform alpha-E preproprotein. Analysis in 22 patients with TB showed increased fibrinogen degradation product (FDP) (5,005 ± 1,297 vs. 4,010 ± 1,181 ng/mL, P < 0.05) and in 142 patients showed elevated plasma fibrinogen levels.

Conclusions

A diagnostic model for TB with high sensitivity and specificity was developed using mass spectrometry combined with magnetic beads. Fibrinogen was identified as a potential biomarker for TB and showed diagnostic values in clinical application.
Appendix
Available only for authorised users
Literature
2.
go back to reference Kirschner DE, Young D, Flynn JL: Tuberculosis: global approaches to a global disease. Curr Opin Biotechnol. 2010, 21: 524-531. 10.1016/j.copbio.2010.06.002.CrossRefPubMedPubMedCentral Kirschner DE, Young D, Flynn JL: Tuberculosis: global approaches to a global disease. Curr Opin Biotechnol. 2010, 21: 524-531. 10.1016/j.copbio.2010.06.002.CrossRefPubMedPubMedCentral
3.
go back to reference Marko-Varga G, Lindberg H, Löfdahl CG, Jönsson P, Hansson L, Dahlbäck M, Lindquist E, Johansson L, Foster M, Fehniger TE: Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J Proteome Res. 2005, 4: 1200-1212. 10.1021/pr050122w.CrossRefPubMed Marko-Varga G, Lindberg H, Löfdahl CG, Jönsson P, Hansson L, Dahlbäck M, Lindquist E, Johansson L, Foster M, Fehniger TE: Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J Proteome Res. 2005, 4: 1200-1212. 10.1021/pr050122w.CrossRefPubMed
4.
go back to reference McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O’Grady J, Pletschette M, Ditui L, Atun R, Zumla A: Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis. 2012, 205: 147-158. 10.1093/infdis/jir860.CrossRef McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O’Grady J, Pletschette M, Ditui L, Atun R, Zumla A: Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis. 2012, 205: 147-158. 10.1093/infdis/jir860.CrossRef
5.
go back to reference Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S: Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011, 11: 2139-2161. 10.1002/pmic.201000460.CrossRefPubMed Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S: Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011, 11: 2139-2161. 10.1002/pmic.201000460.CrossRefPubMed
6.
go back to reference Van Altena R, Duggirala S, Gröschel MI, van der Werf TS: Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des. 2011, 17: 2853-2862. 10.2174/138161211797470228.CrossRefPubMed Van Altena R, Duggirala S, Gröschel MI, van der Werf TS: Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des. 2011, 17: 2853-2862. 10.2174/138161211797470228.CrossRefPubMed
7.
go back to reference Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M: Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract. 2012, 21: 4-13. 10.1159/000331583.CrossRefPubMed Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M: Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract. 2012, 21: 4-13. 10.1159/000331583.CrossRefPubMed
8.
go back to reference Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 2007, 5: 77-85. 10.1016/S1672-0229(07)60018-7.CrossRefPubMed Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 2007, 5: 77-85. 10.1016/S1672-0229(07)60018-7.CrossRefPubMed
9.
go back to reference Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005, 5: 83-89. 10.1186/1471-2407-5-83.CrossRefPubMedPubMedCentral Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005, 5: 83-89. 10.1186/1471-2407-5-83.CrossRefPubMedPubMedCentral
10.
go back to reference Cho WC: Research progress in SELDI-TOF MS and its clinical applications. Chin J Biotech. 2006, 22: 871-876. 10.1016/S1872-2075(06)60061-7.CrossRef Cho WC: Research progress in SELDI-TOF MS and its clinical applications. Chin J Biotech. 2006, 22: 871-876. 10.1016/S1872-2075(06)60061-7.CrossRef
11.
go back to reference Dursun E, Monari E, Cuoghi A, Bergamini S, Ozben B, Suleymanlar G, Tomasi A, Ozben T: Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: effect of darbepoetin treatment. Acta Histochem. 2010, 112: 432-443. 10.1016/j.acthis.2009.04.003.CrossRefPubMed Dursun E, Monari E, Cuoghi A, Bergamini S, Ozben B, Suleymanlar G, Tomasi A, Ozben T: Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: effect of darbepoetin treatment. Acta Histochem. 2010, 112: 432-443. 10.1016/j.acthis.2009.04.003.CrossRefPubMed
12.
go back to reference Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, Wong RM, Chim SS, Ngai SM, Sung JJ, Lo YM: Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem. 2006, 52: 421-429. 10.1373/clinchem.2005.061689.CrossRefPubMed Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, Wong RM, Chim SS, Ngai SM, Sung JJ, Lo YM: Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem. 2006, 52: 421-429. 10.1373/clinchem.2005.061689.CrossRefPubMed
13.
go back to reference Hodgetts A, Levin M, Kroll JS, Langford PR: Biomarker discoveryin infectious diseases using SELDI. Future Microbiol. 2007, 2: 35-49. 10.2217/17460913.2.1.35.CrossRefPubMed Hodgetts A, Levin M, Kroll JS, Langford PR: Biomarker discoveryin infectious diseases using SELDI. Future Microbiol. 2007, 2: 35-49. 10.2217/17460913.2.1.35.CrossRefPubMed
14.
go back to reference World Health Organization: International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association: Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001, 5: 213-215. World Health Organization: International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association: Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001, 5: 213-215.
15.
go back to reference Ligon LS, Hayden JD, Braunstein M: The ins and outs of Mycobacterium tuberculosis protein export. Tuberculosis (Edinb). 2012, 92: 121-132. 10.1016/j.tube.2011.11.005.CrossRef Ligon LS, Hayden JD, Braunstein M: The ins and outs of Mycobacterium tuberculosis protein export. Tuberculosis (Edinb). 2012, 92: 121-132. 10.1016/j.tube.2011.11.005.CrossRef
16.
go back to reference Zhang J, Wu X, Shi L, Liang Y, Xie Z, Yang Y, Li Z, Liu C, Yang F: Diagnostic serum proteomic analysis in patients with active tuberculosis. Clin Chim Acta. 2012, 413: 883-887. 10.1016/j.cca.2012.01.036.CrossRefPubMed Zhang J, Wu X, Shi L, Liang Y, Xie Z, Yang Y, Li Z, Liu C, Yang F: Diagnostic serum proteomic analysis in patients with active tuberculosis. Clin Chim Acta. 2012, 413: 883-887. 10.1016/j.cca.2012.01.036.CrossRefPubMed
17.
go back to reference Sinha S, Kosalai K, Arora S, Namane A, Sharma P, Gaikwad AN, Brodin P, Cole ST: Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology. 2005, 151: 2411-2419. 10.1099/mic.0.27799-0.CrossRefPubMed Sinha S, Kosalai K, Arora S, Namane A, Sharma P, Gaikwad AN, Brodin P, Cole ST: Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology. 2005, 151: 2411-2419. 10.1099/mic.0.27799-0.CrossRefPubMed
18.
go back to reference Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CF, Krishna S: Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet. 2006, 368: 1012-1021. 10.1016/S0140-6736(06)69342-2.CrossRefPubMed Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CF, Krishna S: Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet. 2006, 368: 1012-1021. 10.1016/S0140-6736(06)69342-2.CrossRefPubMed
19.
go back to reference Liu Q, Chen X, Hu C, Zhang R, Yue J, Wu G, Li X, Wu Y, Wen F: Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry. Lung. 2010, 188: 15-23. 10.1007/s00408-009-9199-6.CrossRefPubMed Liu Q, Chen X, Hu C, Zhang R, Yue J, Wu G, Li X, Wu Y, Wen F: Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry. Lung. 2010, 188: 15-23. 10.1007/s00408-009-9199-6.CrossRefPubMed
20.
go back to reference Zheng ZG, Yu HQ, Ling ZQ, Mou HZ, Deng HT, Mao WM: Comprehensive profiling of the low molecular weight proteins and peptides in weak cation exchange beads human serum retentate. Protein Pept Lett. 2011, 18: 498-506. 10.2174/092986611794927983.CrossRefPubMed Zheng ZG, Yu HQ, Ling ZQ, Mou HZ, Deng HT, Mao WM: Comprehensive profiling of the low molecular weight proteins and peptides in weak cation exchange beads human serum retentate. Protein Pept Lett. 2011, 18: 498-506. 10.2174/092986611794927983.CrossRefPubMed
21.
go back to reference Song QB, Hu WG, Wang P, Yao Y, Zeng HZ: Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin. 2011, 32: 1537-1542. 10.1038/aps.2011.137.CrossRefPubMedPubMedCentral Song QB, Hu WG, Wang P, Yao Y, Zeng HZ: Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin. 2011, 32: 1537-1542. 10.1038/aps.2011.137.CrossRefPubMedPubMedCentral
22.
go back to reference Deng B, Dong Z, Liu Y, Wang C, Liu J, Wang C, Qu X: Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads. Clin Chim Acta. 2010, 411: 1051-1057. 10.1016/j.cca.2010.03.036.CrossRefPubMed Deng B, Dong Z, Liu Y, Wang C, Liu J, Wang C, Qu X: Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads. Clin Chim Acta. 2010, 411: 1051-1057. 10.1016/j.cca.2010.03.036.CrossRefPubMed
23.
go back to reference Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P: Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol. 1996, 93: 943-949. 10.1046/j.1365-2141.1996.d01-1722.x.CrossRefPubMed Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P: Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol. 1996, 93: 943-949. 10.1046/j.1365-2141.1996.d01-1722.x.CrossRefPubMed
24.
25.
go back to reference Kwaan HC, Barlow GH: Nature and biological activities of degradation products of fibrinogen and fibrin. Annu Rev Med. 1973, 24: 335-344. 10.1146/annurev.me.24.020173.002003.CrossRefPubMed Kwaan HC, Barlow GH: Nature and biological activities of degradation products of fibrinogen and fibrin. Annu Rev Med. 1973, 24: 335-344. 10.1146/annurev.me.24.020173.002003.CrossRefPubMed
26.
go back to reference Thomas DP, Niewiarowski S, Myers AR, Bloch KJ, Colman RW: A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med. 1970, 283: 663-668. 10.1056/NEJM197009242831301.CrossRefPubMed Thomas DP, Niewiarowski S, Myers AR, Bloch KJ, Colman RW: A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med. 1970, 283: 663-668. 10.1056/NEJM197009242831301.CrossRefPubMed
28.
go back to reference Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005, 3: 1894-1904. 10.1111/j.1538-7836.2005.01365.x.CrossRefPubMed Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005, 3: 1894-1904. 10.1111/j.1538-7836.2005.01365.x.CrossRefPubMed
29.
go back to reference Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A: Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002, 6: 927-932.PubMed Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A: Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002, 6: 927-932.PubMed
30.
go back to reference Awodu OA, Ajayi IO, Famodu AA: Haemorheological variables in Nigeria pulmonary tuberculosis patients undergoing therapy. Clin Hemorheol Microcirc. 2007, 36: 267-275.PubMed Awodu OA, Ajayi IO, Famodu AA: Haemorheological variables in Nigeria pulmonary tuberculosis patients undergoing therapy. Clin Hemorheol Microcirc. 2007, 36: 267-275.PubMed
31.
go back to reference Sakamoto K, Geisel RE, Kim MJ, Wyatt BT, Sellers LB, Smiley ST, Cooper AM, Russell DG, Rhoades ER: Fibrinogen dimycolate regulates the cytotoxicity of mycobacterial trehalose but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun. 2010, 78: 1004-1011. 10.1128/IAI.00451-09.CrossRefPubMed Sakamoto K, Geisel RE, Kim MJ, Wyatt BT, Sellers LB, Smiley ST, Cooper AM, Russell DG, Rhoades ER: Fibrinogen dimycolate regulates the cytotoxicity of mycobacterial trehalose but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun. 2010, 78: 1004-1011. 10.1128/IAI.00451-09.CrossRefPubMed
32.
go back to reference Hernández-Pando R, Arriaga AK, Panduro CA, Orozco EH, Larriva-Sahd J, Madrid-Marina V: The response of hepatic acute phase proteins during experimental pulmonary tuberculosis. Exp Mol Pathol. 1998, 65: 25-36. 10.1006/exmp.1998.2224.CrossRefPubMed Hernández-Pando R, Arriaga AK, Panduro CA, Orozco EH, Larriva-Sahd J, Madrid-Marina V: The response of hepatic acute phase proteins during experimental pulmonary tuberculosis. Exp Mol Pathol. 1998, 65: 25-36. 10.1006/exmp.1998.2224.CrossRefPubMed
33.
go back to reference Magalhães V, Veiga-Malta I, Almeida MR, Baptista M, Ribeiro A, Trieu-Cuot P, Ferreira P: Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes Infect. 2007, 9: 1276-1284. 10.1016/j.micinf.2007.06.001.CrossRefPubMed Magalhães V, Veiga-Malta I, Almeida MR, Baptista M, Ribeiro A, Trieu-Cuot P, Ferreira P: Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes Infect. 2007, 9: 1276-1284. 10.1016/j.micinf.2007.06.001.CrossRefPubMed
34.
go back to reference Rodríguez-Flores E, Campuzano J, Aguilar D, Hernández-Pando R, Espitia C: The response of the fibrinolytic system to mycobacteria infection. Tuberculosis (Edinb). 2012, 92: 497-504. 10.1016/j.tube.2012.07.002.CrossRef Rodríguez-Flores E, Campuzano J, Aguilar D, Hernández-Pando R, Espitia C: The response of the fibrinolytic system to mycobacteria infection. Tuberculosis (Edinb). 2012, 92: 497-504. 10.1016/j.tube.2012.07.002.CrossRef
35.
go back to reference Monroy V, Amador A, Ruiz B, Espinoza-Cueto P, Xolalpa W, Mancilla R, Espitia C: Binding and activation of human plasminogen by Mycobacterium tuberculosis. Infect Immun. 2000, 68: 4327-4330. 10.1128/IAI.68.7.4327-4330.2000.CrossRefPubMedPubMedCentral Monroy V, Amador A, Ruiz B, Espinoza-Cueto P, Xolalpa W, Mancilla R, Espitia C: Binding and activation of human plasminogen by Mycobacterium tuberculosis. Infect Immun. 2000, 68: 4327-4330. 10.1128/IAI.68.7.4327-4330.2000.CrossRefPubMedPubMedCentral
Metadata
Title
The discovery and identification of a candidate proteomic biomarker of active tuberculosis
Authors
Jiyan Liu
Tingting Jiang
Liliang Wei
Xiuyun Yang
Chong Wang
Xing Zhang
Dandan Xu
Zhongliang Chen
Fuquan Yang
Ji-Cheng Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-506

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine